Carlos Singer

Carlos Singer practices at UMiami Medicine - Neurology in Miami, Florida.

Carlos Singer's NPI, 1285654335, was assigned on July 20, 2006. Carlos Singer graduated from Central University of Venezuela in 1972. Carlos Singer holds Florida license ME33954.

Carlos Singer's primary practice is UMiami Medicine - Neurology, at 1150 Nw 14th St, Miami, FL 33136 in Miami-Dade County. The practice phone is (305) 243-4951.

Carlos Singer's primary practice is UMiami Medicine - Neurology in Miami, Florida. Carlos Singer is also affiliated with Sylvester Comprehensive Cancer Center. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Carlos Singer practices. Vendor and product names are available with a free account.

Neurology is Carlos Singer's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Carlos Singer is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Carlos Singer's licenses on file in 2 states: Florida and Pennsylvania.

Dmand AI lists cerebrovascular disease, encephalopathy, essential tremor, hereditary polyneuropathy, muscle disease, neuropathy, non-alzheimer's dementia (chronic) and parkinson's disease among the conditions Carlos Singer treats.

CMS data shows 20,676 Medicare services from Carlos Singer across 10 procedure codes in 2024, for 373 Medicare patients. Medicare paid $171,256 for them. Every service was in an office.

CMS counts 373 Medicare patients who saw Carlos Singer in 2024. The largest group is 75 to 84, with 171 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 16% are also on Medicaid. Their average risk score is 1.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Carlos Singer's median patient age at 72, with 49% women.

In 2024, Carlos Singer wrote 2,738 Medicare Part D claims for 437 patients. 81% of them were for generic drugs. CMS names the drug for 2,517 of them, across 43 drugs with 11 or more claims each, at $762,934 in total drug cost. In 2023, CMS named 2,062 claims across 37 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Carlos Singer for performance year 2024, reported as part of a group. Carlos Singer accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Carlos Singer as offering telehealth.

Dmand AI links 151 papers to Carlos Singer, published from 2005 to 2024. 2017 was the busiest year, with 14. The most frequent topics are Parkinson Disease, Botulinum Toxins, Type A and Double-Blind Method. Carlos Singer has published most often in Mov Disord. Carlos Singer's most frequent co-authors are Jason Margolesky, MD, Henry Paul Moore, MD and Corneliu Luca, MD.

Dmand AI links Carlos Singer to 3 clinical trials. Conditions studied include Caregiver Burden, Microcephaly, Primary Autosomal Recessive, 6 and Urinary Bladder, Overactive.

CMS Open Payments shows 84 general payments to Carlos Singer from 15 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 64% of the total. Teva Pharmaceuticals USA, Inc. paid the most, $5,712.

Dmand AI lists 1 award for Carlos Singer.

Carlos Singer graduated from Central University of Venezuela in 1972.

Carlos Singer is in network with 10 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.